A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Inclusion Criteria: * Previous participation in MI-CP104 and received at least 3 injections of MEDI-524 in MI-CP104 * The child must be less than or equal to 24 months of age at time of entry into the study (child must be entered on or before their 24-month birthday) * The child must be able to complete the follow-up visits through 3-4 months after last dose (total length of participation of 6-8 months) * Written informed consent obtained from the patient's parent(s) or legal guardian Exclusion Criteria: * Currently hospitalized * Receiving chronic oxygen therapy or mechanical ventilation at the time of study entry (including continuous positive airway pressure \[CPAP\]) * Evidence of infection with hepatitis A, B, or C virus * Known renal impairment, hepatic dysfunction, chronic seizure disorder, or immunodeficiency or HIV infection * Suspected serious allergic or immune mediated events with prior receipt of MEDI-524 * Acute illness or progressive clinical disorder * Active infection, including acute respiratory syncytial virus (RSV) infection at the time of enrollment * Previous reaction to IGIV, blood products, or other foreign proteins * Have ever received palivizumab * Received within the past 120 days or currently receiving immunoglobulin products (such as RSV-IGIV \[RespiGam(R)\], IVIG), or any investigational agents (except MEDI-524) * Currently participating in any investigational study